Shots: The P-III EXPAND study involves assessing of Mayzent vs PBO in 1,651 patients with SPMS from 31 countries with varying levels of disability (Core Part), EDSS scores of 3·0–6·5, followed by extended treatment with open-label BAF312 to evaluate long-term safety, tolerability and efficacy The P-III EXPAND study: 52% reduction in ARR in Mayzent group; […]Read More
